MDGL Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences

CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today its management team will participate in fireside chats at two upcoming investor conferences:

Jefferies Healthcare Conference

2:30 pm ET on Wednesday, June 7, 2023.

Goldman Sachs Global Healthcare Conference

12:20 pm ET on Tuesday, June 13, 2023.

The fireside chats will be webcast and archived recordings will be available for replay in the Investors section of the Madrigal after the events.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit .

Investor Contact

Alex Howarth, Madrigal Pharmaceuticals, Inc.,

Media Contact

Christopher Frates, Madrigal Pharmaceuticals, Inc.,



EN
01/06/2023

Underlying

MDGLMadrigal Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Madrigal Pharmaceuticals

 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmeti...

Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis Late-breaking results from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial presented at the EASL Congress65% of patients with clinically significant portal hypertension (CSPH) at baseline moved into lower risk categories by year twoPatients achieved a mean 6.7 kPa reduction in liver stiffness, which was statistically significant compared to baseline CONSH...

8h / 21m 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results ...

Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates First-quarter 2025 Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as oral late-breaker at EASL Congress (May 7-10)Appointed David Soergel, M.D., to Chief Medical Officer; Rebecca Taub, M.D., named Senior Scientific and Medical Advisor Appointed Jacqualyn Fouse, Ph.D., to Board of DirectorsReports cash, cash equivalents, restricted cash and marke...

May 1, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Com...

Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress CONSHOHOCKEN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced six presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from May 7-10, 2025, in Amsterdam, the Netherlands. Madrigal will share detailed two-year data from the open-label compen...

April 29, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Resul...

Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), announced today that it will release its first-quarter 2025 financial results on Thursday, May 1, 2025, prior to the open of the U.S. financial markets. Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to revi...

April 18, 2025 1 EN
 PRESS RELEASE
Free
MDGL Madrigal Pharma...

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. ...

Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer Dr. Taub’s pioneering research in academia and industry led to the first FDA-approved therapy for patients with MASH CONSHOHOCKEN, Pa., April 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that Rebecca Taub, M.D., the company's founder, Chief Med...

April 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch